IOVS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


(Investigative Ophthalmology and Visual Science. 2006;47:917-924.)
© 2006 by The Association for Research in Vision and Ophthalmology, Inc.
DOI:  10.1167/iovs.05-0854

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wild, J. M.
Right arrow Articles by Smith, P. E. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wild, J. M.
Right arrow Articles by Smith, P. E. M.

Detecting Vigabatrin Toxicity by Imaging of the Retinal Nerve Fiber Layer

John M. Wild,1 Catherine R. Robson,1 Adrian L. Jones,2 Ian A. Cunliffe,3 and Philip E. M. Smith4

1From the Cardiff School of Optometry and Vision Sciences, Cardiff University, Cardiff, Wales, United Kingdom; the 2Cardiff Eye Unit and the 4Welsh Epilepsy Unit, University Hospital of Wales, Cardiff, Wales, United Kingdom; and the 3Department of Ophthalmology, Birmingham Heartlands Hospital, Birmingham, United Kingdom.

PURPOSE. To quantify retinal nerve fiber layer thickness (RNFLT) and macular thickness (MT) in patients exhibiting vigabatrin-attributed visual field loss (VAVFL) and to determine the efficacy of these measures as markers of the retinal damage associated with vigabatrin.

METHODS. This was a prospective cross-sectional observational study involving five groups: Group I, 13 patients exhibiting VAVFL; Group II, 8 patients exposed to vigabatrin but with normal fields; Group III, 14 patients receiving carbamazepine monotherapy; Group IV, 20 normal individuals; and Group V, 7 patients receiving sodium valproate monotherapy. At one of two visits, the right eye of each participant underwent two digital imaging modalities: ocular coherence tomography (OCT; StratusOCT; Carl Zeiss Meditec, Dublin, CA) and scanning laser ophthalmoscopy (SLO; Heidelberg Retinal Tomograph; Heidelberg Engineering GmbH, Heidelberg, Germany). At the other visit, participants underwent three-zone, age-corrected suprathreshold perimetry of the whole field and threshold perimetry of the central field (Humphrey Field Analyzer 750; Carl Zeiss Meditec). The order of the visits was randomized.

RESULTS. The group mean RNFLT in Group I was attenuated relative to that of the remaining groups (all P < 0.001). At 100% specificity, based on the 95% confidence limits derived from Group IV, OCT exhibited 100% sensitivity and SLO 77% sensitivity for an attenuated RNFLT in patients with VAVFL. All participants manifested an MT within the normal range derived from Group IV.

CONCLUSIONS. OCT of the RNFL can efficiently identify vigabatrin-induced damage and will be useful for adults and children unable to perform perimetry and when the perimetric outcome is equivocal.





This article has been cited by other articles:


Home page
Arch. Dis. Child.Home page
J. P Osborne, J. Merrifield, and F. J K O'Callaghan
Tuberous sclerosis--what's new?
Arch. Dis. Child., September 1, 2008; 93(9): 728 - 731.
[Full Text] [PDF]


Home page
Arch OphthalmolHome page
R. D. Fechtner, A. S. Khouri, E. Figueroa, M. Ramirez, M. Federico, S. L. Dewey, and J. D. Brodie
Short-term Treatment of Cocaine and/or Methamphetamine Abuse With Vigabatrin: Ocular Safety Pilot Results.
Arch Ophthalmol, September 1, 2006; 124(9): 1257 - 1262.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the Association for Research in Vision and Ophthalmology